LAURUSLABS - Laurus Labs Limited Share Price

In the Q4 FY26 earnings conference call, Laurus Labs management presented an optimistic outlook driven by significant strategic initiatives and ongoing demand in their key markets. Key highlights include projected expansions in capacity and revenue sources aimed at bolstering their CDMO (Contract Development and Manufacturing Organization) business, which now contributes over 30% of total revenues "“ a sharp increase from 13% six years ago.

The company reported total revenues of INR 6,813 crores for FY26, marking a 23% increase, supported mainly by robust growth in the CDMO and generics segments. EBITDA margins improved by 6.7 percentage points to 26.8%, and the profit after tax soared 148% to INR 889 crores, reflecting strong operational execution.

Management emphasized the advancement of several capex projects, with plans to invest around INR 3,000 crores over the next two years, primarily increasing capacities in CDMO and CMO (Contract Manufacturing Organization). Notable projects include:

1. Unit 7: A greenfield manufacturing facility expected to commence commercial validation by March 2027, contributing over 2,000 cubic meters of reactor volume.
2. Peptide Manufacturing Block: Set to validate commercial scale production by Q2 FY27.
3. Laurus Bio Expansion: A new fermentation site anticipated to be operational by end of 2026.

Management foresees continued growth momentum, primarily from late-stage pipeline programs and commercial API supplies, with expectations for CDMO revenue to maintain positive growth. They confirmed a strong sales outlook but noted potential geopolitical disruptions in raw material availability.

For FY27, Laurus expects stable margins and operational leverage as production scales up, positioning the company for sustained growth in both existing and new markets, particularly in non-ARV segments as they strategically reduce dependency on anti-retroviral therapies.

1. Question: "Dr. Satya, as we commission and scale the upcoming Vizag 400 KL fermentation, what could be the single biggest source of yield variability from things such as contamination, oxygen transfer, strain stability to even downstream recovery?"

   Answer: We expect contamination to be the biggest challenge in fermentation. Our initial batches will focus on industrial chemicals, not pharmaceuticals, so they won't have a long, cumbersome downstream process. We're confident operational challenges in downstream manufacturing won't be a concern.

2. Question: "Beyond the R2 at Bengaluru and this 400 KL at Vizag, looking at the horizon beyond 2030, is biotech getting the attention it truly deserves?"

   Answer: Our biotech initiatives include various projects like biocatalysis and gene therapy. Current investments are sizable, focusing on gene therapy, ADC manufacturing, and more. We're analyzing market dynamics and strategizing accordingly for growth in this segment.

3. Question: "Dr. Satya, do we have enough CDMO commercial products to say that we do not have product concentration risk?"

   Answer: We've launched three APIs recently with several years of patent life, and our partners provided clear forecasts. Therefore, we don't anticipate destocking challenges for these products in the foreseeable future.

4. Question: "Is it right to assume that the operating leverage will play significantly over the next two years?"

   Answer: We expect to see operational leverage in our upcoming financials. We continuously expand capacities, and as evidenced by our improving EBITDA margins, we foresee growth.

5. Question: "Regarding the peptide opportunity and its breakthrough chances, how does that look?"

   Answer: We're exploring various sectors for peptides, including weight loss. Medium-term opportunities exist, and once substantial progress is made, we'll inform our partners.

6. Question: "Can you provide the ARV business split between API and formulations?"

   Answer: Typically, our ARV business consists of about two-thirds API and one-third formulations. This ratio may vary slightly from quarter to quarter but broadly aligns with that distribution.

7. Question: "What is your guidance for capex and gross debt outlook for FY '27 and '28?"

   Answer: Our capex guidance is around INR3,000 crores over the next two years. The effective tax rate will be around 25% to 26% for our operations.

8. Question: "With AI disrupting industries, how do you see its impact on the discovery phase?"

   Answer: While we are not directly involved in discovery, AI significantly speeds up molecule generation. However, the impact on our manufacturing operations is minimal as we focus on scaling established processes.

9. Question: "What growth can we expect in the non-ARV formulations for FY '27?"

   Answer: We anticipate continued growth in non-ARV formulations driven by existing products and ramping up capacity utilization. This momentum has been strong in FY '26 and is expected to persist into FY '27.

10. Question: "When can we expect the new greenfield capex of 500 acres in Atchutapuram to come online?"

    Answer: We will provide more details on the timeline for the Atchutapuram greenfield project in the next quarter. Expect updates as the project progresses.